Mankind Pharma Ltd News Today

The cumulative demand, including interest charges, is ₹183.11 crore.

The merger took effect on March 29, 2025, after all necessary regulatory approvals were obtained.

The tax adjustments pertain to Section 80IC/80IE, which involves deductions for businesses in special economic zones, and a disallowance of certain expenditures under Section 37(1) of the Act.

Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.

The company reported a good growth in EBITDA of 36.8% to ₹830 crore in the quarter against ₹606.5 crore in Q3 FY24.

The NCDs issued are categorized, rated, secured, redeemable, and transferable, distributed across three series.

According to the National Cancer Registry Programme, cancer is expected to cause 29.8 million DALYs by 2025, making it a serious health issue in India.

The issue price includes a premium of ₹2,519 per share, aggregating a total of ₹2,999.99 crore.

Revenue from operations grew by 13.6% YoY, totaling ₹3,076.5 Crore, up from ₹2,708.1 Crore in Q2 of the previous fiscal.

Here are some of the stocks that may see significant price movement today: Dr Reddy’s, Hindustan Zinc, Titan Company, etc.